JP2012532624A - 細胞、組成物および方法 - Google Patents

細胞、組成物および方法 Download PDF

Info

Publication number
JP2012532624A
JP2012532624A JP2012520100A JP2012520100A JP2012532624A JP 2012532624 A JP2012532624 A JP 2012532624A JP 2012520100 A JP2012520100 A JP 2012520100A JP 2012520100 A JP2012520100 A JP 2012520100A JP 2012532624 A JP2012532624 A JP 2012532624A
Authority
JP
Japan
Prior art keywords
cells
cell
bcl11b
itnk
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532624A5 (enExample
Inventor
ペンタオ・リュウ
ペン・リ
シャノン・バーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genome Research Ltd
Original Assignee
Genome Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0912287A external-priority patent/GB0912287D0/en
Priority claimed from GBGB1006649.6A external-priority patent/GB201006649D0/en
Application filed by Genome Research Ltd filed Critical Genome Research Ltd
Publication of JP2012532624A publication Critical patent/JP2012532624A/ja
Publication of JP2012532624A5 publication Critical patent/JP2012532624A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012520100A 2009-07-15 2010-07-15 細胞、組成物および方法 Pending JP2012532624A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22577909P 2009-07-15 2009-07-15
GB0912287A GB0912287D0 (en) 2009-07-15 2009-07-15 Cells, compositions and methods
GB0912287.0 2009-07-15
US61/225,779 2009-07-15
GB1006649.6 2010-04-21
GBGB1006649.6A GB201006649D0 (en) 2010-04-21 2010-04-21 Cells, compositions and methods
PCT/GB2010/051158 WO2011007176A1 (en) 2009-07-15 2010-07-15 Cells, compositions and methods

Publications (2)

Publication Number Publication Date
JP2012532624A true JP2012532624A (ja) 2012-12-20
JP2012532624A5 JP2012532624A5 (enExample) 2013-09-05

Family

ID=43448979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520100A Pending JP2012532624A (ja) 2009-07-15 2010-07-15 細胞、組成物および方法

Country Status (4)

Country Link
US (1) US20120288484A1 (enExample)
EP (1) EP2454361A1 (enExample)
JP (1) JP2012532624A (enExample)
WO (1) WO2011007176A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103409466B (zh) * 2013-05-27 2015-01-21 中国科学院广州生物医药与健康研究院 一种使bcl11b蛋白降解的方法
US20190185852A1 (en) * 2016-05-05 2019-06-20 M. Mahmood Hussain Therapeutically modulating apob and apoai
CN112574952B (zh) * 2019-09-30 2025-04-15 英基生物医药(香港)有限公司 一种工程化人体免疫细胞、其制备方法及应用
WO2021129015A1 (zh) * 2019-12-27 2021-07-01 昭泰英基生物医药（香港）有限公司 工程化免疫杀伤细胞、其制备方法和应用
CN111607569A (zh) * 2020-06-01 2020-09-01 广东昭泰体内生物医药科技有限公司 一种基于CRISPR/Cas9重编程ITNK细胞的方法
CN111849919A (zh) * 2020-07-24 2020-10-30 英基生物医药(香港)有限公司 一种具有抗病毒活性的工程化免疫细胞及其构建方法和应用
AU2022271801A1 (en) * 2021-05-13 2023-11-09 Memorial Sloan Kettering Cancer Center Nkg2c+ t cells and methods of use thereof
KR102604208B1 (ko) * 2021-09-10 2023-11-23 한국생명공학연구원 유도 자연살해세포의 제조방법 및 그의 용도
CN119909172A (zh) * 2025-01-15 2025-05-02 华中科技大学同济医学院附属协和医院 过表达slc29a1用于增强t细胞内外活性的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509892A (ja) * 1998-03-27 2002-04-02 ガブリエル ミュルソフ Ｈｓｐ７０タンパク質の新規使用
JP2005320309A (ja) * 2004-05-02 2005-11-17 Hokkaido Technology Licence Office Co Ltd 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509892A (ja) * 1998-03-27 2002-04-02 ガブリエル ミュルソフ Ｈｓｐ７０タンパク質の新規使用
JP2005320309A (ja) * 2004-05-02 2005-11-17 Hokkaido Technology Licence Office Co Ltd 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014045965; Ｄ．Ｉ．Ａｌｂｕ，　ｅｔ　ａｌ: Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．２０４，　Ｎｏ．１２, 2007, ｐ．３００３-３０１５ *

Also Published As

Publication number Publication date
US20120288484A1 (en) 2012-11-15
WO2011007176A1 (en) 2011-01-20
EP2454361A1 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
EP3688142B1 (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
Liu et al. Critical roles of Bcl11b in T‐cell development and maintenance of T‐cell identity
JP2012532624A (ja) 細胞、組成物および方法
JP2021191272A (ja) 万能性細胞のゲノム改変
JP2020528885A (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
CN113766919B (zh) 制造抗bcma car t细胞
AU2016278959A1 (en) CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
Gehre et al. A stromal cell free culture system generates mouse pro‐T cells that can reconstitute T‐cell compartments in vivo
KR20180033537A (ko) Pd-l1 발현 조혈 줄기 세포 및 용도
US20250270506A1 (en) T Cells
JP2013006793A (ja) Ｎｋ細胞を増幅するための組成物及び方法
Zaghi et al. Innate immune responses in the outcome of haploidentical hematopoietic stem cell transplantation to cure hematologic malignancies
US20140037599A1 (en) Compositions and Methods of Treating T Cell Deficiency
JP2021523717A (ja) 代謝、生存、および機能を促進するための免疫細胞におけるａｒｉｄ５ｂ発現の操縦
US20210290672A1 (en) Regulation of tumor-associated t cells
Litjens et al. Allogeneic mature human dendritic cells generate superior alloreactive regulatory T cells in the presence of IL-15
US20220202900A1 (en) Compositions and methods for crispr/cas9 knock-out of cd33 in human hematopoietic stem / progenitor cells for allogenic transplantation in patients with relapsed - refractory acute myeloid leukemia
US20240082398A1 (en) Methods of preparing and expanding type i innate lymphoid cells and therapeutic uses thereof
CN113502265A (zh) 将t细胞重编程为类nk细胞的诱导剂及其应用
CN116113423A (zh) 表达il-10的多供体cd4+t细胞及其用途
US20250290040A1 (en) Gamma delta t cell compositions and methods of use
US20250388646A1 (en) Enhancing effector cell durability and efficacy in adoptive cell therapies
Mujaj et al. Molecular mechanisms influencing NK cell development: implications for NK cell malignancies
He et al. A Microbiota‐and IL‐15‐Dependent Innate‐Like B Cell Progenitor Expressing E4BP4
Zhang et al. Eomesodermin+ CD4+ T cells are critical for curative immunotherapy outcomes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151102